Please use this identifier to cite or link to this item:
http://hdl.handle.net/10397/115018
| DC Field | Value | Language |
|---|---|---|
| dc.contributor | Department of Applied Biology and Chemical Technology | - |
| dc.creator | Hu, MQ | - |
| dc.creator | Chua, SL | - |
| dc.date.accessioned | 2025-09-02T00:32:09Z | - |
| dc.date.available | 2025-09-02T00:32:09Z | - |
| dc.identifier.uri | http://hdl.handle.net/10397/115018 | - |
| dc.language.iso | en | en_US |
| dc.publisher | MDPI AG | en_US |
| dc.rights | © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). | en_US |
| dc.rights | The following publication Hu, M., & Chua, S. L. (2025). Antibiotic-Resistant Pseudomonas aeruginosa: Current Challenges and Emerging Alternative Therapies. Microorganisms, 13(4), 913 is available at https://dx.doi.org/10.3390/microorganisms13040913. | en_US |
| dc.subject | Pseudomonas aeruginosa | en_US |
| dc.subject | Antibiotic resistance | en_US |
| dc.subject | Bacteriophage | en_US |
| dc.subject | Nanoparticle | en_US |
| dc.subject | Antimicrobial peptides | en_US |
| dc.subject | CRISPR | en_US |
| dc.title | Antibiotic-resistant pseudomonas aeruginosa: current challenges and emerging alternative therapies | en_US |
| dc.type | Journal/Magazine Article | en_US |
| dc.identifier.volume | 13 | - |
| dc.identifier.issue | 4 | - |
| dc.identifier.doi | 10.3390/microorganisms13040913 | - |
| dcterms.abstract | Antibiotic-resistant Pseudomonas aeruginosa is a pathogen notorious for its resilience in clinical settings due to biofilm formation, efflux pumps, and the rapid acquisition of resistance genes. With traditional antibiotic therapy rendered ineffective against Pseudomonas aeruginosa infections, we explore alternative therapies that have shown promise, including antimicrobial peptides, nanoparticles and quorum sensing inhibitors. While these approaches offer potential, they each face challenges, such as specificity, stability, and delivery, which require careful consideration and further study. We also delve into emerging alternative strategies, such as bacteriophage therapy and CRISPR-Cas gene editing that could enhance targeted treatment for personalized medicine. As most of them are currently in experimental stages, we highlight the need for clinical trials and additional research to confirm their feasibility. Hence, we offer insights into new therapeutic avenues that could help address the pressing issue of antibiotic-resistant Pseudomonas aeruginosa, with an eye toward practical applications in future healthcare. | - |
| dcterms.accessRights | open access | en_US |
| dcterms.bibliographicCitation | Microorganisms, Apr. 2025, v. 13, no. 4, 913 | - |
| dcterms.isPartOf | Microorganisms | - |
| dcterms.issued | 2025-04 | - |
| dc.identifier.isi | WOS:001475410100001 | - |
| dc.identifier.eissn | 2076-2607 | - |
| dc.identifier.artn | 913 | - |
| dc.description.validate | 202509 bcrc | - |
| dc.description.oa | Version of Record | en_US |
| dc.identifier.FolderNumber | OA_Scopus/WOS | en_US |
| dc.description.fundingSource | Others | en_US |
| dc.description.fundingText | Environment and Conservation Fund (84/2021); Health and Medical Research Fund (HMRF-23220372); Research Centre of Deep Space Explorations (BBFQ and BBCZ); Pneumoconiosis Compensation Fund Board | en_US |
| dc.description.pubStatus | Published | en_US |
| dc.description.oaCategory | CC | en_US |
| Appears in Collections: | Journal/Magazine Article | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| microorganisms-13-00913.pdf | 1.23 MB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.



